The diagnostics firm targets a $3B annual run rate by scaling its Detect platform capacity in the coming years.
Caris Life Sciences forecast 2026 revenue between $1.03 billion and $1.04 billion, driven by expansion of its Detect diagnostic platform. The company aims to reach a $3 billion annual run rate as it scales operations.
The projection follows growth in its testing and data capabilities, though prior revenue figures or consensus estimates were not disclosed. The outlook reflects confidence in demand for precision diagnostics.
No immediate market reaction was reported following the earnings call update.